FUSION ANTIBODIES PLC (FAB) — Full year results briefing

Investor webinar replay

Replay transcript excerpt

Good morning, and welcome to the FUSION ANTIBODIES PLC Investor Presentation. Throughout this recorded presentation, investors will be in listen only mode. Questions are encouraged and they can be submitted at any time using the Q and A tab situated on the right hand corner of your screen. Simply type in your questions and press send. The company may not be in a position to answer every question received during the meeting itself. However, the company can review your questions submitted today and publish responses, which is appropriate to do so. Before we begin, I would like to submit the following poll. And I would now like to hand you over to CEO, Adrian Kincaid. Good morning to you. Thank you, Alex. Good morning, everybody. Thank you for joining us on this IMC. I'm, as as Alex was saying, CEO of FUSION ANTIBODIES. Very pleased to be here. I'm joined today by Steven Smith, our CFO. So without any delay, let's let's give you the latest update on fusion antibodies results for the year ended 03/31/2025. So as per usual, we have a disclaimer, which I'm sure all of who's you who have practiced with this will have read that in just a few seconds. So we'll move on, and I will hand over to Steven to take you through. Thanks, Adrian. Again, by way of introduction, I'm Steven Smith. I am the chief financial officer here at FUSION ANTIBODIES. We'll start with our income statement extract for the most recently audited year with full comparatives. So revenue increased year over year by 73% from 1,136,000 to 1.965, in the year ended 03/31/2025. The first half of, of fiscal twenty twenty five was strong, at 1,200,000, at which point we were slightly ahead of our, internal forecasts. However, h two was much more challenging, with 765,000 of revenue booked in the final six months o...